Adropin as a therapeutic candidate for HFpEF: evidence of oxidative stress mitigation via Nrf2/HO-1 signaling
Adropin improves HFpEF by attenuating metabolic dysregulation, oxidative stress, and myocardial remodeling. Mechanistically, adropin activates the Nrf2/HO-1 pathway, suggesting a novel therapeutic strategy for HFpEF. These findings highlight the potential of adropin to reduce disease burden and improve quality of life in HFpEF patients, addressing critical gaps in current HFpEF management.
Authors
- Bingda Li (ORCID: https://orcid.org/0000-0001-6189-5280)
- Wansong Hu
- Fangpeng Liu (ORCID: https://orcid.org/0009-0009-4991-6347)
- Jingan Rao
- Yongjiang Wu (ORCID: https://orcid.org/0000-0001-6584-8940)
- Ping Li (ORCID: https://orcid.org/0000-0002-9521-6095)
- Qing Zhou (ORCID: https://orcid.org/0000-0002-0069-559X)
- Yu-Xiu Yang
Institutions
- Nanchang University (CN)
- China-Japan Friendship Hospital (CN)
- Jiangxi Science and Technology Normal University (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine (CN)
- First Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1186/s12944-025-02703-6
- Citations
- 2
- Primary Topic
- Adipose Tissue and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province